




Contractor Details	Type/ size of legal entity	Place of performance of contract activities	Logo
<p><u>Main contractor</u></p> <p>QIAGEN GmbH Qiagen-Str. 1 40724 Hilden / Germany Dr. Uwe Oelmüller Phone nr: +49 152 018 11489 uwe.oelmuller@qiagen.com</p>	<p>larger company</p>	<p>% of contract value allocated to main contractor: <u>100 %</u></p> <p>% of activities for the contract performed by the main contractor in EU Member States or countries associated with Horizon 2020: <u>100 %</u></p>	
<p>Project abstract</p> <p>All steps of diagnostic workflows including pre-analytical, analytical and post-analytical steps can influence final diagnostic results. During the development of NGS tests all workflow steps therefore need to be specified, verified and validated.</p> <p>In this project we are developing new NGS suited pre-analytical workflows and their optimised links to NGS library preparation including quality control. Steps will include specimen collection, stabilization, storage, transport, processing and isolation of nucleic acids. Specimen types will include blood, tissues, urine, saliva, and bone marrow. Specimen target analytes will include cellular RNA, genomic DNA, liquid biopsies nucleic acids including ccfDNA and ccfRNA, as well as different cellular features. Multimodality and multisource specimen requirements will be taken into account, being especially important for cancer diagnostics. We will also develop optimised pre-analytical interphase steps to NGS library preparation including library QC.</p> <p>Newest ISO & CEN Standards and EU IVDR 2017/746 requirements will be followed. Complete NGS workflows will be built with existing and upcoming new sequencing and bioinformatics solutions for judging the quality of our new pre-analytical / library solutions.</p>			
<p>Previous EU funding</p> <p>Is the project based on / a continuation of R&D activities that were previously funded by the EU?: <u>YES</u> If yes, identify this EU funding:</p> <ul style="list-style-type: none"> - H2020 — SPIDIA4P — grant agreement no. 733112 - H2020 – EASI-Genomics – grant agreement no. 824110 - H2020 – CANCER-ID – grant agreement no. 115749 - FP7 – SPIDIA – grant agreement no. 222916 			

